Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-07-26Clinical Trial Update: Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes [Phase 4]
Phase 4 trial exploring the effects of pioglitazone and evogliptin on hepatic fibrosis in patients with chronic hepatitis B and type 2 diabe…
-
CLINICAL_TRIALS research · 2022-07-26Clinical Trial Update: Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes [NA]
Clinical trial update on the safety and effectiveness of duodenal mucosal resurfacing (DMR) with the Revita system for type 2 diabetes; stud…
-
CLINICAL_TRIALS trial_result · 2022-07-22Clinical Trial Update: Cinnamomum Cassia Effect on IGF1 and Metabolic Control in Patients With DM2 Without Glycemic Control Metformin Treated [Phase 3]
Phase 3 trial assessing the effect of Cinnamomum cassia on IGF-1 and metabolic control in metformin-treated type 2 diabetes patients with in…
-
CLINICAL_TRIALS trial_result · 2022-07-22Clinical Trial Update: Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes [Phase 2]
Phase 2 trial evaluating dorzagliatin effects on first-phase insulin response and beta-cell glucose sensitivity in type 2 diabetes and monog…
-
CLINICAL_TRIALS trial_result · 2022-07-21Clinical Trial Update: The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects [NA]
A completed clinical trial investigating the effect of sitagliptin (Januvia) on oxidative stress in obese adults with type 2 diabetes.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-07-20Clinical Trial Update: Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes [Phase 4]
Phase 4 trial comparing iGlarLixi to insulin glargine plus dulaglutide for efficacy and safety in type 2 diabetes.
-
CLINICAL_TRIALS trial_result · 2022-07-19Clinical Trial Update: Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin [Phase 3]
Phase 3 trial comparing a fixed-ratio combination of insulin glargine and lixisenatide versus basal insulin glargine in type 2 diabetes pati…
-
CLINICAL_TRIALS trial_result · 2022-07-19Clinical Trial Update: Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s) [Phase 3]
Phase 3 trial evaluating a fixed-ratio combination of insulin glargine and lixisenatide in adults with type 2 diabetes inadequately controll…
-
CLINICAL_TRIALS trial_result · 2022-07-11Clinical Trial Update: A Comparative Study of the Effect of Ayurvedic Drugs and Metformin in the Management of Diabetes Mellitus (Type II) [Phase 3]
Phase 3 trial comparing Ayurvedic drugs to Metformin for Type 2 diabetes has completed.
-
FDA approval · 2022-07-01FDA Approved: TRESIBA — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for TRESIBA (insulin degludec) by Novo Nordisk.
-
FDA approval · 2022-07-01FDA Approved: GLIPIZIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approves a supplemental application for Glipizide from Rising Pharma Holdings, Inc., a generic antidiabetic medication.
-
CLINICAL_TRIALS trial_result · 2022-07-01Clinical Trial Update: A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes [Phase 3]
Phase 3 study of dulaglutide in children and adolescents with type 2 diabetes completed; results posted in 2022.
-
FDA label_change · 2022-07-01FDA Approved: LEVEMIR — Supplemental Application (Novo Nordisk)
FDA approves a supplemental application for LEVEMIR (insulin detemir) from Novo Nordisk. The action updates the product labeling.
-
CLINICAL_TRIALS trial_result · 2022-07-01Clinical Trial Update: Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes [Phase 4]
A Phase 4 trial evaluating the effects of dapagliflozin and metformin on vascular function in newly diagnosed, treatment-naive type 2 diabet…
-
CLINICAL_TRIALS trial_result · 2022-06-30Clinical Trial Update: Tenelia Elderly CGMS Study(TEDDY) [Phase 4]
Phase 4 clinical trial update for Tenelia Elderly CGMS Study (TEDDY) in type 2 diabetes mellitus is completed.
-
CLINICAL_TRIALS trial_result · 2022-06-30Clinical Trial Update: A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus [Phase 2]
A Phase 2 clinical trial assessing the efficacy and safety of PF-06882961 in adults with type 2 diabetes has been completed with results pos…
-
CLINICAL_TRIALS trial_result · 2022-06-30Clinical Trial Update: Evaluation of the Efficacy and Safety of Curalin as Add-On Therapy in Adults With Type 2 Diabetes Mellitus [Phase 2]
Phase 2 trial evaluating Curalin as add-on therapy for adults with type 2 diabetes has completed.
-
EMA withdrawal · 2022-06-28EMA Withdrawn: Starlix (nateglinide) — Novartis Europharm Limited
EMA withdrew Starlix (nateglinide) from the market for Type 2 diabetes.
-
CLINICAL_TRIALS trial_result · 2022-06-23Clinical Trial Update: Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment [Phase 4]
Phase 4 trial comparing Roux-en-Y gastric bypass to best medical treatment in type 2 diabetes patients with BMI 27-32 has completed.
-
FDA approval · 2022-06-21FDA Approved: JANUMET — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for JANUMET (sitagliptin and metformin hydrochloride) filed by Merck Sharp & Dohme LLC.
-
FDA approval · 2022-06-21FDA Approved: JANUMET XR — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for JANUMET XR (sitagliptin and metformin hydrochloride) submitted by Merck Sharp & Dohme LLC, expan…
-
FDA approval · 2022-06-21FDA Approved: STEGLUJAN — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for STEGLUJAN (ertugliflozin and sitagliptin) submitted by Merck Sharp & Dohme LLC.
-
CLINICAL_TRIALS research · 2022-06-21Clinical Trial Update: Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans [NA]
A completed clinical trial evaluating skeletal muscle lipids and their localization effects on insulin resistance in humans, involving Type …
-
CLINICAL_TRIALS trial_result · 2022-06-21Clinical Trial Update: The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus [Phase 2]
Phase 2 trial update evaluating different doses of SY-009 in patients with Type 2 Diabetes Mellitus, focusing on efficacy and safety.
-
CLINICAL_TRIALS trial_result · 2022-06-21Clinical Trial Update: GLP1-imaging Before and After Bariatric Surgery [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating GLP-1 imaging before and after bariatric surgery.